Mutation Analysis of Genes Within the Dynactin Complex in a Cohort of Hereditary Peripheral Neuropathies

Total Page:16

File Type:pdf, Size:1020Kb

Mutation Analysis of Genes Within the Dynactin Complex in a Cohort of Hereditary Peripheral Neuropathies Clin Genet 2016: 90: 127–133 © 2015 John Wiley & Sons A/S. Printed in Singapore. All rights reserved Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12712 Original Article Mutation analysis of genes within the dynactin complex in a cohort of hereditary peripheral neuropathies a a Tey S., Ahmad-Annuar A., Drew A.P., Shahrizaila N., Nicholson G.A., S. Tey , A. Ahmad-Annuar , Kennerson M.L. Mutation analysis of genes within the dynactin complex in A.P. Drewb, N. Shahrizailac, , a cohort of hereditary peripheral neuropathies. G.A. Nicholsonb d and Clin Genet 2016: 90: 127–133. © John Wiley & Sons A/S. Published by M.L. Kennersonb,d John Wiley & Sons Ltd, 2015 aDepartment of Biomedical Science, The cytoplasmic dynein–dynactin genes are attractive candidates for Faculty of Medicine, University of Malaya, b neurodegenerative disorders given their functional role in retrograde Kuala Lumpur, Malaysia, Northcott transport along neurons. The cytoplasmic dynein heavy chain (DYNC1H1) Neuroscience Laboratory, ANZAC Research Institute, and Sydney Medical gene has been implicated in various neurodegenerative disorders, and School, University of Sydney, Sydney, dynactin 1 (DCTN1) genes have been implicated in a wide spectrum of Australia, cDepartment of Medicine, disorders including motor neuron disease, Parkinson’s disease, spinobulbar Faculty of Medicine, University of Malaya, muscular atrophy and hereditary spastic paraplegia. However, the Kuala Lumpur, Malaysia, and dMolecular involvement of other dynactin genes with inherited peripheral neuropathies Medicine Laboratory, Concord Hospital, (IPN) namely, hereditary sensory neuropathy, hereditary motor neuropathy Sydney, Australia and Charcot–Marie–Tooth disease is under reported. We screened eight genes; DCTN1-6 and ACTR1A and ACTR1B in 136 IPN patients using Key words: Charcot–Marie–Tooth – whole-exome sequencing and high-resolution melt (HRM) analysis. Eight dynactin – hereditary motor non-synonymous variants (including one novel variant) and three neuropathies – hereditary sensory synonymous variants were identified. Four variants have been reported neuropathies – peripheral neuropathies previously in other studies, however segregation analysis within family members excluded them from causing IPN in these families. No variants of Corresponding author: Azlina disease significance were identified in this study suggesting the dynactin Ahmad-Annuar, Department of Biomedical Science, Faculty of genes are unlikely to be a common cause of IPNs. However, with the ease of Medicine, University of Malaya, 50603 querying gene variants from exome data, these genes remain worthwhile Kuala Lumpur, Malaysia. candidates to assess unsolved IPN families for variants that may affect the Tel.: +60 37 967 4948; function of the proteins. fax: +60 37 967 6600; e-mail: [email protected] Conflictofinterest Received 2 September 2015, revised The authors declare that they have no conflicts of interest. and accepted for publication 7 December 2015 Inherited peripheral neuropathies (IPN) are a large group complex in patients with a range of neurodegenerative of disorders that can manifest in motor and/or sensory disorders. Mutations in cytoplasmic dynein heavy chain, phenotypes and are increasingly recognized for their DYNC1H1 have been reported in several studies result- phenotypic and genetic heterogeneity. Over 80 genes ing in an axonal form of Charcot–Marie–Tooth (CMT) have been implicated in these disorders and despite the disease, intellectual disability and malformations of cor- wide diversity of function the phenotypes that result tical development (2–4). In addition, mouse mutants of from these mutated genes commonly share a progressive Dync1h1 show neurodegenerative phenotypes in keep- degeneration of the peripheral nerves (1). ing with a motor and sensory phenotype (5–7). Apart Next generation sequencing has expedited the from the heavy chain, within the cytoplasmic dynein identification of causal variants in genes within the complex there are other subunits including the dynein microtubule-associated dynein–dynactin motor protein intermediate chains 1 and 2 (DYNC1I1 and DYNC1I2), 127 Tey et al. light chains (DYNLL1–L2, DYNLRB1, DYNLT1 and Table 1. IPN families screened in this study. The subtype of IPN DYNLT3) and light intermediate chains (DYNC1LI1 and and the methods of candidate gene screening are shown. A total DYNC1LI2). Less is known about the involvement of of the 136 families were screened in which 76 were diagnosed these genes in neurodegenerative phenotypes in humans, with CMT, 29 with HSN and 31 with HMN although studies in mice have shown that a point muta- Number of patients screened tion in Dyncili1 causes anxiety-like behaviour (8). In addition, mutations in the Drosophila dynein light Classes of IPNs WES HRM intermediate chain genes give rise to defects in dendritic CMT (n = 76) morphogenesis through the Rab5 pathway and also in the CMT1 4 0 establishment of axonal and dendritic polarity (9, 10). CMT2 43 0 Recently we reported that genes within the cytoplasmic CMT4 0 1 dynein gene family (DYNC1I1, DYNC1I2, DYNLL1–L2, CMT with 21 DYNLRB1, DYNLT1 and DYNLT3, DYNC1LI1 and pyramidal signs DYNC1LI2) were not associated with IPNs (11). In this CMTX 25 0 study, we have investigated the role of genes within HSN (n = 29) the dynactin complex. Dynactin is a multi-subunit HSN1 1 27 protein complex that is required for a wide range of HSN2 0 1 cellular activities including mitosis and retrograde Other (n = 31) axonal transport. The dynactin complex comprises of HMN 14 0 subunits encoded by eight genes (DCTN1-6, ACTR1A HMNP 15 0 and ACTR1B). Structurally, the dynactin complex is HMNX 2 0 divided into two parts: the projecting side arm consists Total 106 30 of the p150Glued subunit (DCTN1), p22/24 (DCTN3) Gene screening All known IPN PMP22, MPZ, genes and all MFN2, GJB1 and p50/dynamitin (DCTN2); the Arp1 rod consists of a the Arp1 filaments (ACTR1A/1B) and heterotetrameric dynactin genes and all dynactin complex composed of p62 (DCTN4), p25 (DCTN5), p27 genes (except DCTN1) (DCTN6) and Arp11 (12, 13). The Drosophila mutants for the homolog of DCTN1, CMT, Charcot–Marie–Tooth disease; HSN, hereditary sensory p150Glued and mouse models with point mutations in neuropathy; HMN, hereditary motor neuropathy; HMNP, HMN Dctn1 have impaired cargo trafficking, whereas mice with pyramidal signs. overexpressing Dctn1 exhibit motor neuron degeneration aThe known IPN genes are listed (Table S2) and were excluded (14–16). In humans, mutations in DCTN1 are associated as a pathogenic cause in the patients screened by WES. with a form of human spinal muscular atrophy (SMA) and Perry Syndrome, frontotemporal dementia, amy- on the clinical presentation of the patients and family his- otrophic lateral sclerosis (ALS) and Parkinson disease tory. The index patients were further sub-classified into: (17–24). In addition, BICD2 which is an interacting part- demyelinating CMT (CMT1); axonal CMT (CMT2); ner of DCTN2 was recently reported to cause congenital autosomal recessive CMT (CMT4); CMT with pyra- SMA and hereditary spastic paraplegia (25, 26). midal signs; query CMTX and query HMNX as there Although DCTN1 has been implicated in various neu- was no male to male inheritance in these families and rological disorders, the other genes within the complex the females had a less severe phenotype; HMN with have not been studied in detail for a pathogenic role pyramidal signs; adult onset HSN (HSN1); and juvenile in neurodegenerative disease. We screened the coding onset HSN (HSN2) (Table 1). The 106 patients under- exons of the eight genes within the dynactin complex going WES had been screened for the common IPN using a combination of high-resolution melt (HRM) genes (PMP22, MPZ, MFN2 and GJB1) prior to this analysis and whole-exome sequencing (WES). Eleven study and no mutations were identified. Subsequent anal- variants including one novel variant were identified in ysis of the WES data from the 106 patients excluded six of the genes. However, the non-synonymous variants mutations in all the known IPN genes (listed in Table identified did not segregate with the disease phenotype S1, Supporting information). Samples not sent for WES and are probably have no functional effect on the disease. (28 index samples from HSN families, 1 index CMT4 sample and 1 index sample with CMT with pyramidal Materials and methods signs) were excluded for mutations in the common IPN genes prior to this study. In addition, the 29 HSN fam- Patient selection ilies had been excluded for SPTLC1 and SPTLC2 prior Index patients from 136 IPN families were recruited to this study. through the Neurogenetics Clinic Concord Hospital, Sydney. The cohort included 76 CMT patients, 29 Ethics hereditary sensory neuropathy (HSN) patients and 31 hereditary motor neuropathy (HMN) patients. The index Patient ascertainment and collection of blood samples patients were from families with two or more affected for DNA analysis were performed with informed consent individuals. The classification of the disease was based according to protocols approved by the Sydney Local 128 Dynactin genes and peripheral neuropathies Table 2. Dynactin subunits screened in this study Name Symbol Chromosome position Gene ID Number of exons Dynactin 1 (p150) DCTN1 2p13 NM_004082 32 Dynactin 2 (p50/dynamitin) DCTN2 12q13.3 NM_006400 14 Dynactin 3 (p22/p24) DCTN3 9p13 NM_024348 6 Dynactin 4 (p62) DCTN4 5q31-32 NM_001135643.1 14 Dynactin 5 (p25) DCTN5 16p12.2 NM_032486
Recommended publications
  • Identifying Novel Disease-Associated Variants and Understanding The
    Identifying Novel Disease-variants and Understanding the Role of the STAT1-STAT4 Locus in SLE A dissertation submitted to the Graduate School of University of Cincinnati In partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Immunology Graduate Program of the College of Medicine by Zubin H. Patel B.S., Worcester Polytechnic Institute, 2009 John B. Harley, M.D., Ph.D. Committee Chair Gurjit Khurana Hershey, M.D., Ph.D Leah C. Kottyan, Ph.D. Harinder Singh, Ph.D. Matthew T. Weirauch, Ph.D. Abstract Systemic Lupus Erythematosus (SLE) or lupus is an autoimmune disorder caused by an overactive immune system with dysregulation of both innate and adaptive immune pathways. It can affect all major organ systems and may lead to inflammation of the serosal and mucosal surfaces. The pathogenesis of lupus is driven by genetic factors, environmental factors, and gene-environment interactions. Heredity accounts for a substantial proportion of SLE risk, and the role of specific genetic risk loci has been well established. Identifying the specific causal genetic variants and the underlying molecular mechanisms has been a major area of investigation. This thesis describes efforts to develop an analytical approach to identify candidate rare variants from trio analyses and a fine-mapping analysis at the STAT1-STAT4 locus, a well-replicated SLE-risk locus. For the STAT1-STAT4 locus, subsequent functional biological studies demonstrated genotype dependent gene expression, transcription factor binding, and DNA regulatory activity. Rare variants are classified as variants across the genome with an allele-frequency less than 1% in ancestral populations.
    [Show full text]
  • Supplementary Information
    Supplementary Information PathwayMatcher: multi-omics pathway mapping and proteoform network generation Luis Francisco Hernández Sánchez1,2,3, Bram Burger4,5, Carlos Horro4,5, Antonio Fabregat3, Stefan Johansson1,2, Pål Rasmus Njølstad1,6, Harald Barsnes4,5, Henning Hermjakob3,7, and Marc Vaudel1,2,* 1 K.G. Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway 2 Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway 3 European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom 4 Proteomics Unit, Department of Biomedicine, University of Bergen, Bergen, Norway 5 Computational Biology Unit, Department of Informatics, University of Bergen, Bergen, Norway 6 Department of Pediatrics, Haukeland University Hospital, Bergen, Norway 7 Beijing Proteome Research Center, National Center for Protein Sciences Beijing, Beijing, China * To whom correspondence should be addressed Abstract Mapping biomedical data to functional knowledge is an essential task in biomedicine and can be achieved by querying gene or protein identifiers in pathway knowledgebases. Here, we demonstrate that including fine-granularity information such as post-translational modifications greatly increases the specificity of the analysis. We present PathwayMatcher (github.com/PathwayAnalysisPlatform/PathwayMatcher), a bioinformatic application for mapping multi-omics data to pathways and show how this enables the
    [Show full text]
  • Seq2pathway Vignette
    seq2pathway Vignette Bin Wang, Xinan Holly Yang, Arjun Kinstlick May 19, 2021 Contents 1 Abstract 1 2 Package Installation 2 3 runseq2pathway 2 4 Two main functions 3 4.1 seq2gene . .3 4.1.1 seq2gene flowchart . .3 4.1.2 runseq2gene inputs/parameters . .5 4.1.3 runseq2gene outputs . .8 4.2 gene2pathway . 10 4.2.1 gene2pathway flowchart . 11 4.2.2 gene2pathway test inputs/parameters . 11 4.2.3 gene2pathway test outputs . 12 5 Examples 13 5.1 ChIP-seq data analysis . 13 5.1.1 Map ChIP-seq enriched peaks to genes using runseq2gene .................... 13 5.1.2 Discover enriched GO terms using gene2pathway_test with gene scores . 15 5.1.3 Discover enriched GO terms using Fisher's Exact test without gene scores . 17 5.1.4 Add description for genes . 20 5.2 RNA-seq data analysis . 20 6 R environment session 23 1 Abstract Seq2pathway is a novel computational tool to analyze functional gene-sets (including signaling pathways) using variable next-generation sequencing data[1]. Integral to this tool are the \seq2gene" and \gene2pathway" components in series that infer a quantitative pathway-level profile for each sample. The seq2gene function assigns phenotype-associated significance of genomic regions to gene-level scores, where the significance could be p-values of SNPs or point mutations, protein-binding affinity, or transcriptional expression level. The seq2gene function has the feasibility to assign non-exon regions to a range of neighboring genes besides the nearest one, thus facilitating the study of functional non-coding elements[2]. Then the gene2pathway summarizes gene-level measurements to pathway-level scores, comparing the quantity of significance for gene members within a pathway with those outside a pathway.
    [Show full text]
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions
    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
    [Show full text]
  • Autism Multiplex Family with 16P11.2P12.2 Microduplication Syndrome in Monozygotic Twins and Distal 16P11.2 Deletion in Their Brother
    European Journal of Human Genetics (2012) 20, 540–546 & 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12 www.nature.com/ejhg ARTICLE Autism multiplex family with 16p11.2p12.2 microduplication syndrome in monozygotic twins and distal 16p11.2 deletion in their brother Anne-Claude Tabet1,2,3,4, Marion Pilorge2,3,4, Richard Delorme5,6,Fre´de´rique Amsellem5,6, Jean-Marc Pinard7, Marion Leboyer6,8,9, Alain Verloes10, Brigitte Benzacken1,11,12 and Catalina Betancur*,2,3,4 The pericentromeric region of chromosome 16p is rich in segmental duplications that predispose to rearrangements through non-allelic homologous recombination. Several recurrent copy number variations have been described recently in chromosome 16p. 16p11.2 rearrangements (29.5–30.1 Mb) are associated with autism, intellectual disability (ID) and other neurodevelopmental disorders. Another recognizable but less common microdeletion syndrome in 16p11.2p12.2 (21.4 to 28.5–30.1 Mb) has been described in six individuals with ID, whereas apparently reciprocal duplications, studied by standard cytogenetic and fluorescence in situ hybridization techniques, have been reported in three patients with autism spectrum disorders. Here, we report a multiplex family with three boys affected with autism, including two monozygotic twins carrying a de novo 16p11.2p12.2 duplication of 8.95 Mb (21.28–30.23 Mb) characterized by single-nucleotide polymorphism array, encompassing both the 16p11.2 and 16p11.2p12.2 regions. The twins exhibited autism, severe ID, and dysmorphic features, including a triangular face, deep-set eyes, large and prominent nasal bridge, and tall, slender build. The eldest brother presented with autism, mild ID, early-onset obesity and normal craniofacial features, and carried a smaller, overlapping 16p11.2 microdeletion of 847 kb (28.40–29.25 Mb), inherited from his apparently healthy father.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
    [Show full text]
  • Datasheet: VPA00532KT Product Details
    Datasheet: VPA00532KT Description: BETA-CENTRACTIN ANTIBODY WITH CONTROL LYSATE Specificity: BETA-CENTRACTIN Format: Purified Product Type: PrecisionAb™ Polyclonal Isotype: Polyclonal IgG Quantity: 2 Westerns Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Western Blotting 1/1000 PrecisionAb antibodies have been extensively validated for the western blot application. The antibody has been validated at the suggested dilution. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Further optimization may be required dependant on sample type. Target Species Human Species Cross Reacts with: Mouse Reactivity N.B. Antibody reactivity and working conditions may vary between species. Product Form Purified IgG - liquid Preparation 20μl Rabbit polyclonal antibody purified by affinity chromatography Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN3) Stabilisers 2% Sucrose Immunogen Synthetic peptide directed towards the C terminal region of human beta-centractin External Database Links UniProt: P42025 Related reagents Entrez Gene: 10120 ACTR1B Related reagents Synonyms CTRN2 Page 1 of 3 Specificity Rabbit anti Human beta-centractin antibody recognizes beta-centractin also known as actin- related protein 1B or ACTR1B. The ACTR1B gene encodes a 42.3 kDa subunit of dynactin, a macromolecular complex consisting of 10 subunits ranging in size from 22 to 150 kDa.
    [Show full text]
  • Physical and Linkage Mapping of Mammary-Derived Expressed Sequence Tags in Cattle
    Genomics 83 (2004) 148–152 www.elsevier.com/locate/ygeno Physical and linkage mapping of mammary-derived expressed sequence tags in cattle E.E. Connor,a,* T.S. Sonstegard,a J.W. Keele,b G.L. Bennett,b J.L. Williams,c R. Papworth,c C.P. Van Tassell,a and M.S. Ashwella a U.S. Beltsville Agricultural Research Center, ARS, U.S. Department of Agriculture, 10300 Baltimore Avenue, Beltsville, MD 20705, USA b U.S. Meat Animal Research Center, ARS, U.S. Department of Agriculture, P.O. Box 166, Clay Center, NE 68933-0166, USA c Roslin Institute (Edinburgh), Roslin, Midlothian EH25 9PS, Scotland, United Kingdom Received 2 June 2003; accepted 5 July 2003 Abstract This study describes the physical and linkage mapping of 42 gene-associated markers developed from mammary gland-derived expressed sequence tags to the cattle genome. Of the markers, 25 were placed on the USDA reference linkage map and 37 were positioned on the Roslin 3000-rad radiation hybrid (RH) map, with 20 assignments shared between the maps. Although no novel regions of conserved synteny between the cattle and the human genomes were identified, the coverage was extended for bovine chromosomes 3, 7, 15, and 29 compared with previously published comparative maps between human and bovine genomes. Overall, these data improve the resolution of the human–bovine comparative maps and will assist future efforts to integrate bovine RH and linkage map data. Crown Copyright D 2003 Published by Elsevier Inc. All rights reserved. Keywords: RH mapping; Linkage mapping; SNP; Cattle; EST Selection of positional candidate genes controlling eco- pig [4,5], and cattle [6], and serve as a resource for nomically important traits in cattle requires a detailed candidate gene identification.
    [Show full text]
  • DCTN3 Antibody (Internal Region) Peptide-Affinity Purified Goat Antibody Catalog # Af3366a
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 DCTN3 Antibody (internal region) Peptide-affinity purified goat antibody Catalog # AF3366a Specification DCTN3 Antibody (internal region) - Product Information Application WB Primary Accession O75935 Other Accession NP_009165.1, NP_077324.1, 11258, 53598 (mouse), 362504 (rat) Reactivity Human, Mouse, Rat Predicted Dog, Cow Host Goat Clonality Polyclonal Concentration 0.5 mg/ml Isotype IgG Calculated MW 21119 AF3366a (0.03 µg/ml) staining of Human Kidney lysate (35 µg protein in RIPA buffer). DCTN3 Antibody (internal region) - Additional Primary incubation was 1 hour. Detected by Information chemiluminescence. Gene ID 11258 Other Names Dynactin subunit 3, Dynactin complex subunit 22 kDa subunit, p22, DCTN3 {ECO:0000312|EMBL:CAG46687.1}, DCTN22 Format 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. AF3366a (0.2 µg/ml) staining of Mouse (A) and Rat (B) Skeletal Muscle lysates (35 µg Precautions protein in RIPA buffer). Primary incubation DCTN3 Antibody (internal region) is for was 1 hour. Detected by chemiluminescence. research use only and not for use in diagnostic or therapeutic procedures. DCTN3 Antibody (internal region) - Page 1/2 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Background DCTN3 Antibody (internal region) - Protein Information This antibody is expected to recognize both reported isoforms (NP_009165.1; Name DCTN3 NP_077324.1).
    [Show full text]
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • Biological and Prognostic Significance of Chromosome 5Q Deletions in Myeloid Malignancies Aristoteles A.N
    Review Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies Aristoteles A.N. Giagounidis,1Ulrich Germing,2 and Carlo Aul1 Abstract The presence of del(5q), either as the sole karyotypic abnormality or as part of a more complex karyotype, has distinct clinical implications for myelodysplastic syndromes (MDS) and acute myeloid leukemia. The 5qÀ syndrome, a subtype of low-riskMDS, is characterized by an isolated 5q deletion and <5% blasts in the bone marrow and can serve as a useful model for studying the role of 5q deletions in the pathogenesis and prognosis of myeloid malignancies. Recent clinical results with lenalidomide, an oral immunomodulatory drug, have shown durable erythroid responses, including transfusion independence and complete cytogenetic remissions in patients with del(5q) MDS with or without additional chromosomal abnormalities. These results indicate that lenalidomide can overcome the pathogenic effect of 5q deletion in MDS and restore bone marrow balance. The data provide important new insights into the pathobiology of 5q chromo- somal deletions in myeloid malignancies. Cytogenetic abnormalities are detected in the bone marrow of preponderance, refractory macrocytic anemia, normal or high over 50% of patients diagnosed with primary myelodysplastic platelet counts, hypolobulated megakaryocytes, and modest syndromes (MDS) or myeloid leukemias, and up to 80% of leukopenia (11, 14, 17). The prognosis is favorable in 5qÀ patients with secondary or therapy-related MDS (1, 2). These syndrome with relatively low risk of transformation to AML abnormalities can be characterized as being balanced or (11, 18). Although the limits of 5q deletions vary among unbalanced (3, 4). Balanced cytogenetic abnormalities include patients with 5qÀ syndrome, the most frequent deletion is reciprocal translocations, inversions, and insertions (3, 5, 6).
    [Show full text]